The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
The biotech has been singled out for a $1.6bn payment for US Covid-19 vaccine development.
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.